Star ratings cannot separate one women’s telehealth provider from another, because they average unrelated service lines into a single number. Total value is the better comparison: twelve-month landed cost, who reviews the case, how dose changes are handled, whether records transfer out, and what ending a plan costs. Score those five, then read the reviews.
Why a single rating cannot compare two providers
Hers is the women’s brand operated by Hims & Hers Health, and it sells across several categories at once, including weight management, hair loss, skin treatments, mental health, and sexual health. A public rating pools all of them. A customer pleased with a topical hair product and a customer who found the weight plan hard to manage land in the same average, and that average describes neither of them.
The pooling problem is structural rather than particular to one company. Any multi-category telehealth brand produces it, and there is no verifiable public tally that splits a provider’s sentiment cleanly by service line. A comparison built on ratings is therefore a comparison of two blends of unrelated experiences. The only version that holds up is made inside the specific service line being bought, on terms that can be checked before payment.
The five components of total value
Landed cost across twelve months comes first, because headline monthly pricing hides dose escalation, plan length, labs, and shipping. Clinical depth is second: whether a licensed prescriber reviews the case at every change or only at intake. Continuity is third, meaning what happens when a dose needs adjusting or a side effect appears halfway through a cycle.
Portability is fourth. Prescription records, lab results, and visit notes belong to the patient, and a provider that makes them awkward to export raises the cost of leaving. Exit terms are fifth: the named cancellation method, the notice window, and whether an unshipped order can be refunded. Those five explain far more about eventual satisfaction than any rating does.
| Dimension | Question to ask before paying | Why review scores miss it |
|---|---|---|
| Twelve-month cost | What is the price at maintenance strength, not the first month | Most reviewers post during month one |
| Clinical depth | Who reviews a dose change, and within what window | Invisible until something needs to change |
| Product status | An FDA-approved brand-name drug or a compounded preparation | Reviewers rarely separate the two |
| Continuity | What happens if a side effect appears mid-cycle | Only a minority of customers ever test it |
| Portability | Can records and lab results be exported on request | Almost never mentioned in a review |
| Exit terms | Which cancellation channel counts as notice | Described mainly by people who left unhappy |
The field a Hers shopper is realistically choosing between
In weight management the cash-pay field includes Ro, LifeMD, Noom, WeightWatchers, and Found, alongside marketplace options such as Sesame and PlushCare and the older route of a primary care prescription filled at a retail pharmacy. In skin the nearest equivalents are subscription dermatology services such as Curology. In mental health the comparison set is Brightside or Talkspace, not any weight platform.
Those names differ in how openly they price the weight category itself. Ro and LifeMD post plan structures on their own sites, Henry Meds and Hims and Hers set out cash-pay tiers, the manufacturer channel LillyDirect sells brand supply directly, and HealthRX lists the specific GLP-1 medications it works with alongside the monitoring attached to them. Reading three or four of these next to each other, rather than trusting one pooled score, gives a shopper a real basis for choosing.
These are separate markets with separate economics, which is precisely why one score cannot serve all of them. Inside the weight category the meaningful split is between programs supplying an FDA-approved brand-name drug and programs supplying a compounded preparation, because only the first has an approved label standing behind it.
Price disclosure is where cash-pay programs separate most visibly. Some publish the price of every strength and the plan length before intake, others reveal both only after a consultation fee has been taken, and FormBlends is among the physician-supervised providers putting medication pricing and plan terms in front of the patient at the decision point. Any provider that answers the strength question in writing makes a twelve-month figure calculable.
What published evidence settles, and what it leaves open
Randomized trials establish what the molecules do, not what a provider is worth. Once-weekly semaglutide was studied in the STEP program and tirzepatide in the SURMOUNT program. Those were separate trials with different populations and entry criteria, so placing their headline numbers side by side is a cross-trial comparison rather than a head-to-head result. Clinical practice guidelines for obesity pharmacotherapy describe how these drugs should be selected and monitored, and monitoring is exactly the part a provider either delivers or does not.
Compounded preparations sit outside that evidence base. They are not FDA-approved, which means the agency has not assessed the specific preparation for safety, effectiveness, or manufacturing quality. Published work on direct-to-consumer telemedicine quality describes the matching gap on the service side: convenience models can compress the clinical assessment, and platforms differ mainly in how much assessment survives that compression.
Costs that appear after the first month
Dose escalation is the largest hidden variable. Approved labeling for this drug class sets out a stepped titration schedule, so the strength a customer starts on is rarely the one they stay on, and pricing tied to strength moves with it. Labs, when required, are a separate line. Shipping for temperature-sensitive products may be charged per order rather than per plan.
Plan length is the last one. A discounted headline figure often reflects a prepaid multi-month commitment, and the discount only holds if the full term is used. Multiplying the first month by twelve produces a number that almost no customer actually pays.
Frequently asked questions
Is a higher-rated provider usually the better choice?
Not reliably. Ratings for multi-category telehealth brands blend hair, skin, mental health, and weight customers into one figure, and the mix differs between companies. A provider with a lower score in a category you are not buying may be the stronger option in the one you are.
Which alternatives are genuinely comparable to a Hers weight plan?
Cash-pay weight programs such as Ro, LifeMD, Noom, WeightWatchers, and Found sit in the same market, as do marketplace consultations through Sesame or PlushCare. A primary care visit with a pharmacy fill belongs in the comparison too, especially where insurance covers part of the drug cost.
Does compounded medication make a provider a worse option?
It makes the option different rather than automatically worse. Compounded preparations are not FDA-approved, so the approved label evidence does not transfer to them. The relevant questions become which pharmacy fills the prescription and how closely a licensed prescriber supervises the course.
How much should insurance coverage change the comparison?
Substantially, when it applies. Coverage for weight medication varies by plan and by program type, and Medicare drug coverage rules differ again. A covered brand-name prescription can cost less across a year than any cash-pay subscription, so checking the plan formulary before comparing cash prices is worth the time.
What single figure best summarizes total value?
The cost of twelve months at the strength most people end up on, plus labs and shipping, divided by nothing. Comparing that number across providers, with the product status and the exit terms noted beside it, settles most comparisons that a star rating leaves open.
